Overview

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2023-01-05
Target enrollment:
Participant gender:
Summary
This is a phase I, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of ASC10 tablets and an open-label, crossover design to evaluate the food effect on PK of ASC10 in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Ascletis Pharmaceuticals Co., Ltd.